World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.
autoimmunity
biologic agents
blistering disease
mucous membrane pemphigoid
pemphigus vulgaris
rituximab
Journal
Oral diseases
ISSN: 1601-0825
Titre abrégé: Oral Dis
Pays: Denmark
ID NLM: 9508565
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
07
02
2019
revised:
23
02
2019
accepted:
25
02
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
3
1
2020
Statut:
ppublish
Résumé
To assess the evidence for treatment of oral involvement of pemphigus and pemphigoid with biologics. This systematic review used a comprehensive search strategy to identify literature describing oral involvement of pemphigus or pemphigoid treated with a biologic agent. The primary outcome measures were efficacy and safety of biologic therapy. Inclusion criteria were met by 154 studies including over 1200 patients. Treatment of pemphigus with a total of 11 unique biologic agents and 3 unique combinations of agents is reported. Five randomized controlled trials (RCT) were included in the final analysis that investigated infliximab, IVIg, rituximab, and autologous platelet-rich plasma therapy for pemphigus vulgaris. Three non-RCT studies reported on successful rituximab or IVIg therapy for mucous membrane pemphigoid. Studies demonstrated considerable heterogeneity in agent, methods, and quality. Evidence clearly describing oral tissue response to biologic therapy is sparse. Two RCTs support use of rituximab, one supports use of IVIg, and one pilot study suggests intralesional injection of autologous platelet-rich plasma aids healing of oral PV lesions. As oral lesions of pemphigus and pemphigoid can be refractory to systemic therapy, drug trials including biologic therapies should document details regarding response of the oral lesions to therapy.
Identifiants
pubmed: 31140696
doi: 10.1111/odi.13083
pmc: PMC6544168
mid: NIHMS1016283
doi:
Substances chimiques
Biological Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Systematic Review
Langues
eng
Pagination
111-121Subventions
Organisme : Intramural NIH HHS
ID : Z99 DE999999
Pays : United States
Organisme : Colgate-Palmolive
Organisme : WWOM VII: American Academy of Oral Medicine, European Association of Oral Medicine
Organisme : Xerostom
Organisme : Intramural NIH HHS
ID : ZIA DE000747-02
Pays : United States
Organisme : Unilever
Organisme : NIDCR NIH HHS
ID : R13 DE027613
Pays : United States
Organisme : Henry Schein Cares Foundation
Organisme : Oral Diseases, and The World Dental Education Foundation
Organisme : The British Society for Oral Medicine
Organisme : AFYX
Organisme : The National Institute of Dental and Craniofacial Research
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.
Références
J Am Acad Dermatol. 2001 Nov;45(5):679-90
pubmed: 11606916
Clin Immunol. 2002 Jan;102(1):59-67
pubmed: 11781068
Clin Exp Immunol. 2002 Sep;129(3):533-40
pubmed: 12197896
Arch Dermatol Res. 2003 Apr;295 Suppl 1:S12-6
pubmed: 12677427
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
N Engl J Med. 2006 Oct 26;355(17):1772-9
pubmed: 17065638
Br J Dermatol. 2007 Feb;156(2):352-6
pubmed: 17223877
J Am Acad Dermatol. 2007 Jun;56(6):960-7
pubmed: 17368865
N Engl J Med. 2007 Aug 9;357(6):545-52
pubmed: 17687130
Indian J Pathol Microbiol. 2007 Jul;50(3):498-501
pubmed: 17883117
J Eur Acad Dermatol Venereol. 2008 May;22(5):580-4
pubmed: 18194237
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
J Am Acad Dermatol. 2008 Jun;58(6):1043-6
pubmed: 18339444
J Neurol. 2008 Jul;255 Suppl 3:3-6
pubmed: 18685919
J Invest Dermatol. 2009 Feb;129(2):289-301
pubmed: 19148218
J Am Acad Dermatol. 2009 Apr;60(4):595-603
pubmed: 19293008
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Yale J Biol Med. 2010 Mar;83(1):1-9
pubmed: 20351977
J Am Acad Dermatol. 2013 Mar;68(3):404-11
pubmed: 23044076
PLoS One. 2012;7(12):e50696
pubmed: 23226536
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
Eur J Dermatol. 2013 Jan-Feb;23(1):40-8
pubmed: 23400331
Arch Dermatol Res. 2014 Jan;306(1):67-74
pubmed: 23591742
J Eur Acad Dermatol Venereol. 2014 Jun;28(6):771-80
pubmed: 23651052
Br J Dermatol. 2014 Jun;170(6):1341-9
pubmed: 24640990
Br J Dermatol. 2015 Mar;172(3):760-8
pubmed: 25123295
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):405-14
pubmed: 25338479
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Aug;120(2):132-42.e61
pubmed: 25934414
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Aug;120(2):161-71.e20
pubmed: 25953640
Autoimmun Rev. 2015 Oct;14(10):930-51
pubmed: 26117595
Cancer Immunol Res. 2016 May;4(5):383-9
pubmed: 26928461
Eur J Dermatol. 2016 Aug 1;26(4):382-7
pubmed: 27300747
Science. 2016 Jul 8;353(6295):179-84
pubmed: 27365313
Support Care Cancer. 2017 May;25(5):1713-1739
pubmed: 28224235
JCI Insight. 2017 Mar 9;2(5):e92021
pubmed: 28289723
Lancet. 2017 May 20;389(10083):2031-2040
pubmed: 28342637
Nat Rev Dis Primers. 2017 May 11;3:17026
pubmed: 28492232
J Am Acad Dermatol. 2018 Feb 10;:null
pubmed: 29438767
Arch Dermatol Res. 2018 May;310(4):375-381
pubmed: 29525907
Transfusion. 2018 Jun;58(6):1494-1499
pubmed: 29542126
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Oct;84(4):349-55
pubmed: 9347496